HN
Hansa Biopharma AB
HNSBF · OTC
$3.70 +0.00% (+$0.00)
Market Cap 3.63B kr
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 19.19x
EV/FFO N/A
P/E N/A
Growth
79 /100
Growing Rev. growth 12.88%
Book val. growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 310.69%
Gross margin 57.34%
FCF margin 288.18%
Quality
3 /100
Poor Asset turnover 0.18x
ROIC 71.73%
ROA 71.74%
Debt
23 /100
High Int. coverage -3.06x
Current ratio 1.25x
Debt/Assets N/A
Stability
39 /100
Moderate EPS volatility 32.73%
Beta 1.58x
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o HNSBF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Renée Julie Elisabet Aguiar-Lucander
Employees
125
Headquarters
Lund
Nadchodzące wydarzenia
05 LIS
Earnings
Upcoming earnings report